ESTRO 2022 - Abstract Book

S599

Abstract book

ESTRO 2022

Conclusion The effect of lung dose response was constant across the two groups. Other variables, such as surgery and chemotherapy presented larger variations. While the models fit the cohort they originate from well, they over/underestimated the probability of RP in the respective other cohort. This was possibly caused by the underlying changes in treatment strategies, or by patient selection, and highlights the need for continuous model adaption.

PD-0665 Geriatric Stage III NSCLC: Which scoring systems could guide us better to predict treatment outcome?

F. Sert 1 , F. Farzam 1 , D. Yalman 1 , S. Ozkok 1

1 Ege University Faculty of Medicine, Radiation Oncology, Izmir, Turkey

Purpose or Objective To define the roles of the scoring systems used in predicting the prognosis for geriatric patients with the diagnosis of non- small cell lung cancer (NSCLC) and to create a nomogram for predicting survival. Materials and Methods A total of 78 geriatric ( ≥ 70 years) patients with a diagnosis of stage III NSCLC who received definitive 60-66 Gy radiotherapy (RT) between 2006-2018, and followed up ≥ 6 months, were included.Pretreatment G8 score, Glasgow prognostic score(GPS), and prognostic nutritional index(PNI) results were recorded. Patients were grouped according to the manuals of these scoring systems, and the relationship between overall survival(OS), local recurrence-free survival(LRFS), and distant metastasis-free survival(DMFS) rates and scores were evaluated for each groups.Nomogram was generated only for OS to consider age-related factors. Results The median age of the patients was 74 (range, 70-85) years and 71 (91%) were male. The patients were staged as stage IIIA 37 (47.4%), stage IIIB 35 (44.9%), and stage IIIC 6 (7.7%).The median OS, LRFS, and DMFS rates for all patients were 24, 20, and 19 months, respectively. GPS classifies patients as GPS 0, 1, and 2 based on serum CRP and albumin levels. Accordingly, the distributions of our patients on GPS-0, GPS-1 and GPS-2 were 28 (35.9%), 31 (39.7%) and 19 (24.4%), respectively. The G8 score is a system consisting of age, weight loss, mobility, presence of neuropsychological problems, BMI, comorbidities and patient awareness. In our study, the median G8 score was 10.5 (range, 4.5-17.0) and ≤ 10.5 in 40 (51.3%) patients; It is >10.5 in 38 (48.7%) of them. PNI is calculated by serum albumin and total lymphocyte values. Our median PNI value was calculated as 45.5 (range, 20.0-63.0), and 37 (47.4%) of the patients were <45 and 41 (52.6%) were ≥ 45. No difference was seen between the distribution according to the stages and the risk groupings. In univariate analysis; low GPS (2-y 78%, 52% and 10%, p<0.001), G8 score >10.5 (2-y 28% versus 76%, p<0.001) and PNI ≥ 45 (2-y 37% vs 52%, p=0.014) were found to be favorable factors for OS. Only the G8 score >10.5 (2-y 35% vs 65%, p<0.001) was seen as a positive factor for LRFS. In multivariate analysis; GPS (p=0.005) and G8 score (p=0.011) for OS and G8 score for LRFS (p=0.008) were significant factors.